Evidence map›Paper›PMID 41673707›Full record

ArticleBiomarker research2026

RBM10 modulation of circRNA biogenesis contributes to its tumor suppressor role in lung adenocarcinoma.

Ana Utrilla-Maestre, Ana M Matia-González, Paola Peinado, Maria Angeles Becerra-Rodriguez, Maria S Benitez-Cantos, Marta Cuadros, Pedro P Medina

Abstract readLetter
In one paragraph

Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Utrilla-Maestre *Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain.
Ana M Matia-González *Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain.
Paola Peinado *Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain.
Maria Angeles Becerra-RodriguezDepartment of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain.
Maria S Benitez-CantosGENYO. Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Marta CuadrosGENYO. Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Pedro P MedinaDepartment of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada, Spain. pedromedina@ugr.es.

Funding

Fundación Científica Asociación Española Contra el Cáncer LAB-AECC.2018Junta de Andalucía 24653, PREDOC_00294Junta de Andalucía PI-0203-2022Junta de Andalucía Programa Operativo de Empleo Juvenil y de la Iniciativa de Empleo Juvenil 2021-2023 n° 8114Ministerio de Ciencia e Innovación PID2024-159252OB-I00Ministerio de Ciencia, Innovación y Universidades FPU19/00576Ministerio de Ciencia, Innovación y Universidades PID2021-126111OB-I00Universidad de Granada C-EXP-051-UGR23Universidad de Granada P20-19
6 · The paper itself

Abstract

Circular RNAs (circRNAs) are emerging regulators in cancer biology, yet the mechanisms underlying their biogenesis remain incompletely defined. RBM10, a splicing regulator frequently mutated in lung adenocarcinoma (LUAD), modulates RNA processing, but its involvement in circRNA regulation has not yet been addressed. Transcriptomic profiling of RBM10-restored LUAD cells, followed by RT-qPCR validation, identified circHIPK3 and circSMARCA5 as consistently RBM10-dependent circRNAs. Subcellular fractionation confirmed nuclear confinement of RBM10 and cytoplasmic enrichment of circRNAs, supporting a nuclear role for RBM10 in circRNA biogenesis. PAR-CLIP and RNA pulldown assays demonstrated direct RBM10 binding to intronic flanking regions of these circRNAs. Using a splicing reporter assay, we found that RBM10 binding to the 3' flanking region promotes exon skipping and circularization more efficiently than 5' binding, revealing a position-dependent mechanism controlling circRNA output. Analysis of RBM10 point mutants showed impaired regulation of circHIPK3 and circSMARCA5, linking defective exon skipping to disrupted circRNA formation. Functionally, modulation of circHIPK3 and circSMARCA5 phenocopied RBM10 restoration in mutant LUAD cell lines and rescued the tumorigenic phenotype driven by RBM10 loss. In two independent LUAD cohorts, circHIPK3 was consistently downregulated, particularly in RBM10-mutant tumors, and strongly correlated with RBM10 expression. Proteomic analyses further identified RBM10–SF3B1 interaction as a key upstream event governing circHIPK3 biogenesis. Together, these findings uncover a previously unrecognized mechanism through which RBM10 exerts tumor-suppressive functions via circRNA regulation and highlight circHIPK3 as a promising biomarker and potential therapeutic target in RBM10-deficient LUAD.

Indexed as

Back-splicingcircHIPK3circSMARCA5Circular RNALUADRBPs

Identifiers

PMID41673707
PMCPMC12895834

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.